ArticleApplied biochemistry and biotechnology2025
Engineering Escherichia coli for Efficient Production of L-Tryptophan.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in the microbial biosynthesis of ʟ-tryptophan and its derivatives.Biodesign research · 2025Review
- A comprehensive review of genomic-scale genetic engineering as a strategy to improve bacterial productivity.Microbiology (Reading, England) · 2025Review
- Characterization of the antagonistic secondary metabolites ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
L-tryptophan is an essential amino acid widely used in animal feed, food additives, and pharmaceuticals. Although the biosynthesis of L-tryptophan from renewable raw materials is sustainable and environmentally friendly, its long synthetic pathway and complex regulatory mechanisms often result in low production efficiency. In this study, multiple strategies were employed to improve L-tryptophan production in Escherichia coli. These strategies included three main ones: the introduction of anti-feedback inhibition mutations, the overexpression of key rate-limiting enzymes, and the blockage of competitive and catabolic pathways. Additionally, the glucose transport system was modified by replacing it with a non-phosphoenolpyruvate (PEP)-dependent system, thereby reducing PEP consumption. In addition, overexpression of an L-tryptophan transporter protein enhanced L-tryptophan efflux and alleviated product inhibition. Consequently, an efficient L-tryptophan-producing E. coli strain was constructed. Furthermore, dynamic regulation of L-tryptophan synthesis was initially explored by employing a temperature-sensitive promoter to modulate the PEP metabolic pathway. Scale-up fermentation in a 5-L bioreactor demonstrated that the final strain (TY9) produced 34.1 g·L
Indexed as
Identifiers
40138134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.